Smith & Nephew PLC
SNN
Company Profile
Business description
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Contact
Hatters Lane
Building 5, Croxley Park
WatfordHertfordshireWD18 8YE
GBRT: +44 1923477100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
17,349
Stocks News & Analysis
stocks
Palantir earnings: AI leadership intact; valuation still causes heartburn
Our view of Palantir Technologies.
stocks
As Nvidia crosses $5 trillion, 5 charts on the unstoppable tech rally
Demand for AI has catapulted tech stocks into the stratosphere.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,071.20 | 19.30 | -0.21% |
| CAC 40 | 8,043.69 | 23.84 | -0.30% |
| DAX 40 | 23,776.35 | 172.76 | -0.72% |
| Dow JONES (US) | 47,085.24 | 251.44 | -0.53% |
| FTSE 100 | 9,698.87 | 16.09 | -0.17% |
| HKSE | 25,935.41 | 16.99 | -0.07% |
| NASDAQ | 23,348.64 | 486.09 | -2.04% |
| Nikkei 225 | 50,212.27 | 1,284.93 | -2.50% |
| NZX 50 Index | 13,620.98 | 15.02 | 0.11% |
| S&P 500 | 6,771.55 | 80.42 | -1.17% |
| S&P/ASX 200 | 8,802.00 | 7.80 | -0.09% |
| SSE Composite Index | 3,969.25 | 9.06 | 0.23% |